Undisclosed Small Molecule Modulators
Alzheimer's Disease, ALS, Parkinson's Disease, and other protein aggregation diseases
Pre-clinicalActive
Key Facts
Indication
Alzheimer's Disease, ALS, Parkinson's Disease, and other protein aggregation diseases
Phase
Pre-clinical
Status
Active
Company
About ADRx
ADRx is a private, pre-clinical stage biotech leveraging a proprietary structure-based design platform to create novel small molecule therapeutics for protein aggregation diseases, including Alzheimer's, ALS, and Parkinson's. The company claims to be the first to successfully apply this approach to disrupt pathological protein structures derived from patients. Its strategy involves targeting both amyloid aggregates and biomolecular condensates, representing a potentially transformative approach in a field with high unmet need. As a platform company, ADRx is likely seeking partnerships and investment to advance its internal pipeline.
View full company profile